RPG Life Sciences is strategically enhancing its active pharmaceutical ingredients (APIs) business, with managing director Ashok Nair highlighting its potential as a key growth driver. The company is targeting entry into the GLP-1 (Glucagon-like peptide-1) weight-loss therapy market by August-September, while exploring acquisitions worth ₹600–1,000 crore to scale up operations. Following a challenging year, RPG Life Sciences reported a 144% year-on-year growth in its API business for the March quarter, recovering from disruptions caused by a fire at one of its plants. Nair emphasized the company's focus on niche, complex chemistries with lower competition, aiming to introduce five products annually over the next three years. Despite geopolitical tensions, the company has not faced significant operational disruptions and is actively managing supply chain and cost pressures. RPG Life Sciences is also expanding into cardiology and urology therapy areas, with domestic formulations outperforming the market. The board has recommended a final dividend of ₹24 per equity share for 2025-26, subject to shareholder approval.